GLOBUS MEDICAL, INC. Net Income (Loss) Available to Common Stockholders, Basic
GLOBUS MEDICAL, INC. (GMED) reported Net Income (Loss) Available to Common Stockholders, Basic of $151.57 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2026-08-06
- GLOBUS MEDICAL, INC. net income (loss) available to common stockholders, basic for the quarter ending 2026-06-30 was $151.57M, a 25.28% decline year-over-year.
- GLOBUS MEDICAL, INC. net income (loss) available to common stockholders, basic for the quarter ending 2026-03-31 was $124.30M, a 64.72% increase year-over-year.
- GLOBUS MEDICAL, INC. net income (loss) available to common stockholders, basic for the quarter ending 2025-12-31 was $140.59M, a 430.44% increase year-over-year.
- GLOBUS MEDICAL, INC. net income (loss) available to common stockholders, basic for the quarter ending 2025-09-30 was $118.97M, a 129.50% increase year-over-year.
- GLOBUS MEDICAL, INC. net income (loss) available to common stockholders, basic for fiscal 2025 was $537.87M, a 422.28% increase from fiscal 2024.
- GLOBUS MEDICAL, INC. net income (loss) available to common stockholders, basic for fiscal 2024 was $102.98M, a 16.19% decline from fiscal 2023.
- GLOBUS MEDICAL, INC. net income (loss) available to common stockholders, basic for fiscal 2023 was $122.87M, a 35.39% decline from fiscal 2022.
- GLOBUS MEDICAL, INC. net income (loss) available to common stockholders, basic for fiscal 2022 was $190.17M, a 27.47% increase from fiscal 2021.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | $151.57M 10-Q · filed 2026-08-06 | $275.87M 10-Q · filed 2026-08-06 | $416.46M derived: sum of 3 quarters · filed 2026-08-06 | $535.43M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $124.30M 10-Q · filed 2026-05-07 | $264.89M derived: sum of 2 quarters · filed 2026-05-07 | $383.86M derived: sum of 3 quarters · filed 2026-05-07 | $586.71M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $140.59M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $259.56M derived: sum of 2 quarters · filed 2026-02-24 | $462.41M derived: sum of 3 quarters · filed 2026-08-06 | $537.87M 10-K · filed 2026-02-24 |
| 2025-09-30 | $118.97M 10-Q · filed 2025-11-06 | $321.81M derived: sum of 2 quarters · filed 2026-08-06 | $397.27M 10-Q · filed 2025-11-06 | $423.78M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $202.85M 10-Q · filed 2026-08-06 | $278.31M 10-Q · filed 2026-08-06 | $304.81M derived: sum of 3 quarters · filed 2026-08-06 | $356.65M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $75.46M 10-Q · filed 2026-05-07 | $101.97M derived: sum of 2 quarters · filed 2026-05-07 | $153.80M derived: sum of 3 quarters · filed 2026-05-07 | $185.56M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $26.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $78.34M derived: sum of 2 quarters · filed 2026-02-24 | $110.10M derived: sum of 3 quarters · filed 2026-02-24 | $102.98M 10-K · filed 2026-02-24 |
| 2024-09-30 | $51.84M 10-Q · filed 2025-11-06 | $83.60M derived: sum of 2 quarters · filed 2025-11-06 | $76.48M 10-Q · filed 2025-11-06 | $91.51M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $31.76M 10-Q · filed 2025-08-07 | $24.64M 10-Q · filed 2025-08-07 | $39.68M derived: sum of 3 quarters · filed 2026-02-24 | $40.67M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | -$7.12M 10-Q · filed 2025-05-08 | $7.92M derived: sum of 2 quarters · filed 2026-02-24 | $8.91M derived: sum of 3 quarters · filed 2026-02-24 | $66.63M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $15.03M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $16.03M derived: sum of 2 quarters · filed 2026-02-24 | $73.74M derived: sum of 3 quarters · filed 2026-02-24 | $122.87M 10-K · filed 2026-02-24 |
| 2023-09-30 | $998.00K 10-Q · filed 2024-11-05 | $58.71M derived: sum of 2 quarters · filed 2024-11-05 | $107.84M 10-Q · filed 2024-11-05 | $157.90M derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-06-30 | $57.71M 10-Q · filed 2024-08-06 | $106.84M 10-Q · filed 2024-08-06 | $156.91M derived: sum of 3 quarters · filed 2025-02-20 | $204.34M derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-03-31 | $49.13M 10-Q · filed 2024-05-07 | $99.19M derived: sum of 2 quarters · filed 2025-02-20 | $146.63M derived: sum of 3 quarters · filed 2025-02-20 | |
| 2022-12-31 | $50.06M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | $97.50M derived: sum of 2 quarters · filed 2025-02-20 | $190.17M 10-K · filed 2025-02-20 | |
| 2022-09-30 | $47.43M 10-Q · filed 2023-11-07 | $140.10M 10-Q · filed 2023-11-07 | ||
| 2021-12-31 | $149.19M 10-K · filed 2024-02-21 | |||
| 2012-06-30 | $15.65M 10-Q/A · filed 2012-09-19 | $30.12M 10-Q/A · filed 2012-09-19 | ||
| 2011-06-30 | $13.10M 10-Q/A · filed 2012-09-19 | $24.98M 10-Q/A · filed 2012-09-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSULET CORP (PODD) | United States | $9.420B | 28.12 |
| GLAUKOS Corp (GKOS) | United States | $9.135B | -43.73 |
| BAXTER INTERNATIONAL INC (BAX) | United States | $12.139B | -10.35 |
| Penumbra Inc (PEN) | United States | $12.596B | 77.33 |
| MiniMed Group, Inc. (MMED) | United States | $5.748B | -16.85 |
| MERIT MEDICAL SYSTEMS INC (MMSI) | United States | $5.212B | 28.44 |
| TELEFLEX INC (TFX) | United States | $5.093B | -5.44 |
| Solventum Corp (SOLV) | United States | $15.085B | 9.16 |
| HAEMONETICS CORP (HAE) | United States | $4.821B | 36.52 |
| Heartflow, Inc. (HTFL) | United States | $4.225B |